MoneyWorks4Me

Bacil Pharma - Quaterly Results

16 May 2023 Evaluate
A slight decline in the revenue of Rs. 0.00 millions was seen for the March 2023 quarter as against Rs. 0.00 millions during year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -0.76 millions as compared to Net Loss of Rs. -37.37 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to -0.75% as compared to -37.36% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 0.09 0.08 12.50 1.15 0.58 98.28 1.15 0.58 98.28
PBIDT -0.75 -37.36 -97.99 -0.99 -38.56 -97.43 -0.99 -38.56 -97.43
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT -0.75 -37.36 -97.99 -0.99 -38.56 -97.43 -0.99 -38.56 -97.43
Depreciation 0.01 0.01 0.00 0.03 0.04 -25.00 0.03 0.04 -25.00
PBT -0.76 -37.37 -97.97 -1.02 -38.60 -97.36 -1.02 -38.60 -97.36
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -0.76 -37.37 -97.97 -1.02 -38.60 -97.36 -1.02 -38.60 -97.36
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..